The Business Research Company’s 2026 market reports include new capabilities such as market attractiveness scoring and analysis, total addressable market analysis, company scoring matrix, interactive excel data dashboard, improved supply chain analysis, upcoming startups in the market, and overview of key products, aimed at improving the depth, usability, and strategic value of the insights delivered.
What Is The Forecasted Market Value Of The Artificial Intelligence (AI) In Drug Discovery Market Across 2026–2030?
The artificial intelligence (AI) in drug discovery market has experienced significant expansion in recent years. This market is forecast to increase from $2.33 billion in 2025 to $2.93 billion in 2026, achieving a compound annual growth rate (CAGR) of 25.9%. Historically, this market’s expansion has been propelled by factors such as higher pharmaceutical research and development spending, the increasing intricacy of drug discovery pipelines, the growing availability of biological and chemical datasets, the initial implementation of machine learning in bioinformatics, and more frequent collaborations between pharmaceutical and technology companies.
The artificial intelligence (AI) in drug discovery market is anticipated to experience substantial growth over the next few years. It is expected to expand to $7.42 billion by 2030, exhibiting a compound annual growth rate (CAGR) of 26.2%. This growth during the forecast period is fueled by the escalating adoption of generative AI models, an increasing demand for precision therapeutics, the broadening application of AI-enabled clinical trial design, rising investments in cloud-based discovery platforms, and the regulatory acceptance of AI-assisted drug development. Significant trends projected for the forecast period involve a greater emphasis on AI-driven target identification, the growing utilization of deep learning for molecule screening, the increasing integration of virtual drug screening platforms, the expansion of AI-based lead optimization tools, and a heightened focus on accelerating drug development timelines.
Download the Free Sample Report to Explore Key Market Insights:
https://www.thebusinessresearchcompany.com/sample.aspx?id=3411&type=smp
Which Market Drivers Are Supporting The Expansion Of The Artificial Intelligence (AI) In Drug Discovery Market?
The increasing need for personalized medicine is anticipated to fuel the expansion of artificial intelligence (AI) in the drug discovery market. Personalized medicine involves a tailored method for preventing, diagnosing, and treating diseases, utilizing an individual’s genetic, proteomic, or biological makeup to inform clinical choices. The growing acceptance of personalized medicine stems from a greater necessity for accurate, patient-specific treatments that enhance therapy success and minimize unwanted side effects. AI facilitates this change by speeding up the discovery of molecular targets, refining potential drug candidates, and improving clinical judgment across the entire development process. A relevant example highlights this trend: in February 2024, the U.S. FDA approved 26 new personalized treatments in 2023, encompassing 20 new molecular entities and 6 gene- or cell-based therapies, as reported by the Personalized Medicine Coalition, a US-based advocacy and research organization. Consequently, the rising demand for personalized medicine is powering the growth of artificial intelligence (AI) in the drug discovery market.
What Segmentation Levels Are Considered In The Artificial Intelligence (AI) In Drug Discovery Market?
The artificial intelligence (AI) in drug discovery market covered in this report is segmented –
1) By Technology: Context-Aware Processing, Natural Language Processing, Deep Learning
2) By Drug Type: Small Molecules, Large Molecules
3) By Therapeutic Type: Metabolic Disease, Cardiovascular Disease, Oncology, Neurodegenerative Diseases, Anti-Infective Diseases, Respiratory Diseases, Other Therapeutics
4) By End User: Pharmaceutical Companies, Biopharmaceutical Companies, Academic And Research Institutes, Other End-Users
Subsegments:
1) By Context-Aware Processing: Contextual Data Integration, Predictive Modeling, Adaptive Learning Systems
2) By Natural Language Processing (NLP): Text Mining And Analysis, Drug Interaction Extraction, Clinical Trial Data Analysis
3) By Deep Learning: Neural Networks, Convolutional Neural Networks (CNNs), Recurrent Neural Networks (RNNs), Reinforcement Learning Applications
How Are Trends Shaping The Direction Of The Artificial Intelligence (AI) In Drug Discovery Market?
Leading corporations are channelling investments into companies specializing in artificial intelligence within the drug discovery market, aiming to identify and design novel therapies and subsequently offer these models to other drugmakers. This strategic funding is essential for the research and development of new drugs, a process known for being both costly and protracted. Such financial support helps companies propel their drug discovery initiatives forward and bring innovative treatments to market. As an illustration, in July 2023, Nvidia, a US-based software company, invested $50 million in Recursion Pharmaceuticals, a US-based biotech company that employs artificial intelligence for drug discovery. This investment is intended to assist Recursion in accelerating the development of its AI foundation models for biology and chemistry by leveraging Nvidia’s cloud services.
Which Leading Firms Are Contributing To The Growth Of The Artificial Intelligence (AI) In Drug Discovery Market?
Major companies operating in the artificial intelligence (AI) in drug discovery market are Exscientia, Insilico Medicine, Owkin Inc., XtalPi Inc., Standigm Inc., Innoplexus AG, Atomwise, Inc., BenevolentAI, Deep Genomics Inc., NuMedii, Inc., Verge Genomics, Inc., Berg LLC, Cyclica Inc., Iktos, Quris, Adagene Inc., Gero Pte. Ltd., IBM Corporation, Microsoft Corporation, NVIDIA Corporation, Alphabet Inc., DeepMind Technologies Limited, IQVIA Holdings Inc., GNS Healthcare, Inc., GE HealthCare Technologies Inc., Novartis AG, Pfizer Inc., F. Hoffmann-La Roche Ltd., Merck & Co., Inc., AbbVie Inc., AstraZeneca PLC, Amgen Inc., GlaxoSmithKline plc, Johnson & Johnson, Takeda Pharmaceutical Company Limited, Ipsen S.A., Galderma S.A.
Read the full artificial intelligence (ai) in drug discovery market report here:
How Is The Artificial Intelligence (AI) In Drug Discovery Market Distributed Across Key Geographic Regions?
North America was the largest region in the artificial intelligence (AI) in drug discovery market in 2025. Western Europe was the second largest region in the global artificial intelligence (AI) in drug discovery market share. The regions covered in the artificial intelligence (AI) in drug discovery market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Request A Tailored Artificial Intelligence (AI) In Drug Discovery Market Research Report For Competitive Advantage:
https://www.thebusinessresearchcompany.com/customise?id=3411&type=smp
Browse Through More Reports Similar to the Global Artificial Intelligence (AI) In Drug Discovery Market 2026, By The Business Research Company
Generative Artificial Intelligence Ai In Drug Discovery Global Market Report
Artificial Intelligence Ai In Biopharmaceuticals Global Market Report
Artificial Intelligence Ai In Predictive Toxicology Global Market Report
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas +1 310-496-7795
Asia +44 7882 955267 & +91 8897263534
Europe +44 7882 955267
Email us at info@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
